These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37876091)

  • 1. FDA Approves Tebentafusp-Tebn For Unresectable Or Metastatic Uveal Melanoma.
    Abbas Z; Wally HT; Qureshi FA
    J Pak Med Assoc; 2023 Oct; 73(10):2127. PubMed ID: 37876091
    [No Abstract]   [Full Text] [Related]  

  • 2. Tebentafusp: First Approval.
    Dhillon S
    Drugs; 2022 Apr; 82(6):703-710. PubMed ID: 35364798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
    Chen LN; Carvajal RD
    Expert Rev Anticancer Ther; 2022 Oct; 22(10):1017-1027. PubMed ID: 36102132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tebentafusp-tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal Melanoma.
    Hua G; Carlson D; Starr JR
    J Adv Pract Oncol; 2022 Sep; 13(7):717-723. PubMed ID: 36199496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors.
    Liu AW; Wei AZ; Maniar AB; Carvajal RD
    Expert Opin Biol Ther; 2022 Aug; 22(8):997-1004. PubMed ID: 35060440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
    Nathan P; Hassel JC; Rutkowski P; Baurain JF; Butler MO; Schlaak M; Sullivan RJ; Ochsenreither S; Dummer R; Kirkwood JM; Joshua AM; Sacco JJ; Shoushtari AN; Orloff M; Piulats JM; Milhem M; Salama AKS; Curti B; Demidov L; Gastaud L; Mauch C; Yushak M; Carvajal RD; Hamid O; Abdullah SE; Holland C; Goodall H; Piperno-Neumann S;
    N Engl J Med; 2021 Sep; 385(13):1196-1206. PubMed ID: 34551229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tebentafusp for the treatment of metastatic uveal melanoma.
    Schank TE; Hassel JC
    Future Oncol; 2022 Apr; 18(11):1303-1311. PubMed ID: 35172589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New drug approval: Tebentafusp for treatment of metastatic uveal melanoma HLA A*02:01-positive patients].
    Gaillard A; Matet A; Rodrigues M
    Bull Cancer; 2023 Jan; 110(1):9-10. PubMed ID: 36357199
    [No Abstract]   [Full Text] [Related]  

  • 9. Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.
    Wang Z; Xie Y; Wang JQ; Cheng Y; Fleishman J; Chen ZS; Chen Y
    Drugs Today (Barc); 2023 Mar; 59(3):179-193. PubMed ID: 36847626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.
    Carvajal RD; Butler MO; Shoushtari AN; Hassel JC; Ikeguchi A; Hernandez-Aya L; Nathan P; Hamid O; Piulats JM; Rioth M; Johnson DB; Luke JJ; Espinosa E; Leyvraz S; Collins L; Goodall HM; Ranade K; Holland C; Abdullah SE; Sacco JJ; Sato T
    Nat Med; 2022 Nov; 28(11):2364-2373. PubMed ID: 36229663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma.
    Fahmy LM; Schreidah CM; McDonnell DE; Carvajal RD; Magro CM; Geskin LJ
    Dermatol Online J; 2023 Dec; 29(6):. PubMed ID: 38478664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor lysis syndrome induced by tebentafusp.
    Ruf T; Leonhardt A; Anz D; Kunz WG; Röhrle N; Foerster P; Tomsitz D; French LE; Seegräber M; Heinzerling L
    Immunotherapy; 2023 Nov; 15(16):1363-1368. PubMed ID: 37661909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Plasma Circulating Tumor DNA With Diagnosis of Metastatic Uveal Melanoma.
    Francis JH; Canestraro J; Brannon AR; Barker CA; Berger M; Shoushtari AN; Abramson DH
    JAMA Ophthalmol; 2021 Nov; 139(11):1244-1245. PubMed ID: 34529013
    [No Abstract]   [Full Text] [Related]  

  • 14. Multinodular goiter and primary hyperparathyroidism: a circuitous route to diagnosing metastatic uveal melanoma.
    Theoharis CG; Carling T; Buza N; Zambrano E; Sosa JA
    Endocr Pathol; 2008; 19(4):294-8. PubMed ID: 18758693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sepsis-like cytokine release syndrome after application of tebentafusp in metastasized uveal melanoma.
    Geidel G; Abeck F; Hansen I; Kött J; Heidrich I; Rünger A; Hildebrandt L; Gebhardt C
    J Eur Acad Dermatol Venereol; 2024 Jun; 38(6):e473-e475. PubMed ID: 38059699
    [No Abstract]   [Full Text] [Related]  

  • 16. The risk of other primary cancer in patients with uveal melanoma: a retrospective cohort study of a Canadian population.
    Callejo SA; Al-Khalifa S; Ozdal PC; Edelstein C; Burnier MN
    Can J Ophthalmol; 2004 Jun; 39(4):397-402. PubMed ID: 15327105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations.
    Montazeri K; Pattanayak V; Sullivan RJ
    Drug Des Devel Ther; 2023; 17():333-339. PubMed ID: 36785760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Therapeutic Potential of Histone Deacetylase 6 Inhibitors for Primary and Metastatic Uveal Melanoma.
    Sundaramurthi H; Giricz Z; Kennedy BN
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic uveal melanoma. A morphologic and immunohistochemical analysis.
    Luyten GP; Mooy CM; Post J; Jensen OA; Luider TM; de Jong PT
    Cancer; 1996 Nov; 78(9):1967-71. PubMed ID: 8909318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic uveal melanoma: biology and emerging treatments.
    Woodman SE
    Cancer J; 2012; 18(2):148-52. PubMed ID: 22453016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.